The number of tumor-infiltrating lymphocytes is known to be related to outcomes in patients with a variety of malignancies. Interferon (IFN) g-inducible protein-10 (IP-10) and monokine induced by IFNg (MIG) have chemotactic effects on activated T lymphocytes and natural killer (NK) cells. The aim of this study was to evaluate the antitumor effects of exogenous expression of the MIG and IP-10 genes delivered to solid tumors by poly [D,L-2,4-diaminobutyric acid] (PDBA). The murine MIG and IP-10 genes were transfected into mouse neuroblastoma cells with PDBA. MIG and IP-10 levels in supernatants of transfected cells were measured by enzyme-linked immunosorbent assay. The chemotactic activities of MIG and IP-10 in the supernatants of cell cultures were measured by chemotaxis assay. Tumors were injected in vivo with PDBA/pmMIGHIP-10 complexes to evaluate the effects of these genes on tumor volume and survival time of mice. Transfected PDBA/pmMIGHIP-10 complexes produced MIG and IP-10 protein in vitro. MIG and IP-10 proteins secreted into the culture medium showed chemotactic activity. MIG and IP-10 gene therapy with the PDBA system in vivo significantly inhibited tumor growth and prolonged survival time of mice. In conclusion, PDBA-mediated MIG and IP-10 gene therapy may be useful for treatment of solid tumors.
Introduction
Cytokine-mediated gene transfer is a new strategy for cancer treatment. In particular, chemokine-mediated gene transfer is an attractive and novel method for treatment of cancer. Chemokines comprise a family of factors that act as chemoattractants of immune cells in normal, damaged and tumor tissues. 1 Recently, suppression of tumor growth by transfer of genes encoding chemokines into tumor cells has been reported. [2] [3] [4] Intratumoral injection of an adenoviral vector encoding macrophage-derived chemokine (MDC, CCL22) results in marked tumor regression. 2 Other chemokines, such as RANTES (CCL5) 3 and lymphotactine (XCL1), 4 also show strong antitumor activity in solid tumor models. These results suggest that chemokines can mediate innate and adoptive antitumor immune responses through recruitment of monocytes, dendritic cells (DC), natural killer (NK) cells and T lymphocytes to tumor sites.
Monokine induced by interferon (IFN)g (MIG, CXCL9) and IFNg-inducible protein-10 (IP-10, CXCL10) are included in the CXC chemokine subfamily. MIG is a non-Glu-Leu-Arg (ERL) CXC chemokine 5, 6 and its receptor, CXCR3, is expressed primarily on T cells and NK cells. 7, 8 MIG also contains a long C-terminal extension that is subject to inactivation by proteolytic processing. 6, 9 Expression of MIG is induced by IFNg and released from cells such as macrophages, endothelial cells and non-neoplastic liver cells. 6 MIG is a chemotactic factor for T cells, particularly activated T cells, and has been shown to induce adhesion of activated T cells to endothelial cells. 6, 7 IP-10 is also a non-ELR CXC chemokine that is released from most cells in response to both type I and type II IFN. IP-10 is also a chemotactic factor for activated T cells and NK cells, which activate CXCR3 when stimulated by IP-10.
7,10,11 IP-10 plays an important role in recruiting activated T cells to sites of tissue inflammation.
There are several reported methods for vector-mediated gene transfer into tumor cells. These vectors can be divided into two groups, viral and non-viral. Current methods of viral gene transfer, including adenovirus- 12, 13 and retrovirus-based 14 methods, have high transfection efficiencies. Although the transfection efficiencies of non-viral gene transfer methods are lower than those of viral-mediated methods, non-viral methods are safer and less labor intensive than viral methods, which makes nonviral methods advantageous for clinical use. We recently developed a novel non-viral cytokine gene delivery system based on poly [D,L-2,4-diaminobutyric acid] (PDBA). 15 PDBA differs from poly-lysine in the length of the side chain, resulting in high transfection efficiency. IL-12 gene transfer into tumor cells with the PDBA system induced high levels of production of IL-12 protein, resulting in inhibition of tumor growth. 15 Lymphocytes are often a major component of the mononuclear cells that infiltrate solid tumors. The tumorhost interaction plays an important role in human neoplasm, [16] [17] [18] [19] [20] [21] [22] [23] and it has been suggested that cancer patients with tumors containing large numbers of tumorinfiltrating lymphocytes (TILs) tend to have better prognose than do patients with few TILs. In rapidly proliferating breast tumors, lymphocyte infiltration is a significant predictor for recurrence-free survival. 18 The presence of histiocytes around lung and gastric tumors correlates well with less aggressive behavior of these neoplasms, 19, 20 and in patients with malignant melanoma, rapid lymphocyte infiltration appears to be an indicator of good prognosis. 21, 22 In addition, it has been reported that most TILs are T cells. 24, 25 We hypothesized that PDBA-mediated transfer of the MIG and IP-10 genes into solid tumors may increase the numbers of TILs and enhance antitumor effects at the tumor site. Therefore, in the present study, we evaluated the effectiveness of PDBA-mediated delivery of the MIG and IP-10 genes for treatment of solid tumors in mice.
Materials and methods

Tumor cell lines and animals
Mouse neuroblastoma cell line C1300 26 was kindly provided by Dr A Nishizono (Department of Microbiology, Oita University Faculty of Medicine, Oita, Japan). Cells were maintained in Rosewell Park Memorial Institute (RPMI) 1640 medium supplemented with 10% fetal bovine serum (FBS), 100 IU/ml penicillin and 100 mg/ml streptomycin (Invitrogen, Grand Island, NY).
Female A/J mice (7 weeks old) were purchased from Seac Yoshitomi (Fukuoka, Japan) and housed in the Laboratory Animal Research Center of Oita University (Oita, Japan). Mice were maintained on ad libitum rodent feed and water and were acclimated in the research center at 231C with 50% humidity for at least 1 week before tumor implantation. All studies were performed in accordance with an animal protocol approved by the Oita University Institutional Animal Care and Use Committee.
Plasmids and preparation of PDBA/pDNA complex Mouse MIG and IP-10 expression plasmid pBLASTmMIGHIP-10 were purchased from InvivoGen (San Diego, CA). A plasmid encoding the enhanced green fluorescent protein (EGFP) gene was provided by Hisamitsu Pharmaceutical (Ibaraki, Japan). Plasmid DNAs (pDNAs) were expanded in Escherichia coli strain JM109 (Takara Bio, Shiga, Japan), and pDNAs were isolated and purified with the Qiagen Plasmid Maxi Kit (Hilden, Germany). PDBA was provided by Hisamitsu Pharmaceutical (Ibaraki, Japan). PDBA/pDNA complexes were prepared as described previously. 15 In brief, the concentration of pDNA was measured by UV absorption at 260 nm. PDBA was diluted in phosphatebuffered saline (PBS) to 50 mg/ml and pDNAs were diluted in PBS to 150 mg/ml. Equal volume of diluted PDBA and pDNAs were mixed and PDBA/pDNA complexes were prepared by gentle vortexing. PDBA/ pDNA complexes were used for gene transfection within 60 min of preparation.
Study 1: protein expression and chemotactic activity after PDBA-mediated MIG and IP-10 gene transfer to the cultured C1300 cells Gene transfection. Before in vitro gene transfection, adherent C1300 cells were trypsinized, washed with PBS and collected. Prepared PDBA/pDNA complexes (800 ml) were added to the cells pellet and the mixture was incubated for 1 min. Four milliliters of Opti-MEM (Invitrogen) were then added and the mixture was incubated at 371C for 3 h. The C1300 cells were then collected by centrifugation and cultured in serum-free RPMI 1640 medium. Measurements of MIG and IP-10 protein expression. MIG and IP-10 levels secreted by transfected cells were determined by enzyme-linked immunosorbent assay (ELISA) as previously described. 27 In brief, 1.0 Â 10 6 transfected cells were seeded in six-well tissue culture plates with 3 ml of serum-free RPMI 1640 medium. After 24, 48 or 72 h of incubation, cell culture medium were centrifuged for 3 min at 3000 g and collected. Concentrations of MIG and IP-10 were measured with Quantikine ELISA Kits (R&D Systems, Minneapolis, MN) according to the manufacturer's instructions. A microtiter plate was coated with a monoclonal antibody specific for murine MIG (mMIG) or murine IP-10 (mIP-10). mMIG and/or mIP-10 present in the samples were bound by the immobilized antibody. After several washes to remove unbound proteins, an enzyme-linked polyclonal antibody was added to the wells to bind mMIG or mIP-10. After a second wash, the substrate solution was added and color development was measured with a spectrophotometer at a wavelength of 450 nm. The protein level in the samples was then calculated from a standard curve. PBS (control group) and pmMIGHIP-10 were used as controls.
To determine how long the gene expression was sustained in C1300 cells after PDBA-mediated gene transfer, concentrations of MIG and IP-10 were also measured until day 7 after gene transfer. Transfected cells (1.0 Â 10 5 ) were seeded in 24-well tissue culture plates with 1 ml of RPMI 1640 medium supplemented with 10% FBS, 100 IU/ml penicillin and 100 mg/ml streptomycin (Invitrogen). Cell culture medium was collected and replaced with new RPMI 1640 medium every 2 days after the first day. Concentrations of MIG and IP-10 in each sample were measured with Quantikine ELISA Kits (R&D Systems) as described above. PBS (control group) was used as a control.
Chemotaxis assay. Lymphoid cells were obtained from splenocytes of female A/J mice. Lymphocyte migration was quantified by a modification of the Boyden chamber technique with a 5-mm pore polycarbonate filter in 24-well transwell chambers (Corning Life Science, Acton, MA) as described previously. 28 In brief, 1 Â 10 6 cells suspended in 100 ml RPMI plus 0.5% FBS were added to the upper chamber. Various concentrations of recombinant mMIG (PeproTech, London, UK) and mIP-10 (PeproTech) or conditioned media of transfected C1300 cells were added to the lower chamber of the transwell (600 ml). mMIG and mIP-10 were diluted in PBS to 10 or 100 ng/ml. After 3 h of incubation at 371C under 5% CO 2 , cells that had transmigrated into the lower chamber were collected and washed twice with PBS containing 1% bovine serum albumin (BSA) and 0.1% sodium azide. Cells were then stained with fluorescein isothiocyanate (FITC)-labeled monoclonal antibodies against CD3, CD4 and MAC-1 and phycoerythrin (PE)-labeled monoclonal antibodies against CD8 and CD25 (all from Immunotech, Marseille, France). Cell suspensions were incubated for 30 min at 41C in a fluorescence-activated cell sorter (FACS) analysis tube and washed twice with PBS containing 1% BSA and 0.1% sodium azide. Cells stained with each monoclonal antibody were resuspended in 1 ml PBS with 1% paraformaldehyde and quantified by FACSCalibur and CellQuest software for 30 s at a flow rate of 60 ml/min. MIG and IP-10 at concentrations of 100 ng/ml were used as positive controls. PBS was used as a negative control. The number of CD3-, CD4-, CD8-, CD25-and MAC-1-positive cells that migrated in response to the supernatants of transfected C1300 cells were compared with the positive and negative control values. . Mice were randomly assigned to one of four groups to evaluate the antitumor effect of PDBA-mediated mMIGHIP-10 gene transfer. These groups were control (PBS), plasmid control (pmMIGHIP-10 solution), gene transfer control (PDBA/ pEGFP complex) and PDBA/pmMIGHIP-10 group (PDBA/pmMIG/IP-10 complex). Mice underwent intratumoral injection of 250 ml PBS, pmMIGHIP-10 solution, PDBA/pEGFP complex and PDBA/pmMIG/IP-10 complex, respectively. Injection was given at 7 and 14 days after tumor inoculation. Tumor size was measured every 3 or 4 days for a period of 28 days after gene transfection, and tumor volume was calculated according to the formula V ¼ A Â B 2 /2, where A is the largest diameter (mm) and B is the smallest diameter (mm) of the tumor. PDBA/pEGFP complex, gene transfer control and control groups each comprised 9 animals, and the plasmid control group comprised 7 animals.
Measurement of tumor MIG and IP-10 protein levels. C1300 cells in solid tumors were collected to quantify mMIG and mIP-10 production. Tumor samples were handled as described previously. 15 In brief, mice were killed on the first or third day after gene transfection and tumors were removed. Tumors were washed in PBS and placed in 400 ml T-PER Tissue Protein Extraction Reagent (Pierce Biotechnology, Rockford, IL) until they dissolved. Samples were centrifuged for 3 min at 3000 g, and supernatants collected. Total protein content for each sample was determined with a DC Protein Assay kit (Bio-Rad, Hercules, CA). Concentrations of mMIG and mIP-10 were measured with Quantikine ELISA kits (R&D Systems) as described above.
Analysis of TILs induced by intratumoral MIG and IP-10 gene transfer. Flow cytometric analysis was performed to evaluate the number of infiltrating lymphocytes in the solid tumors, as previously described. 29 In brief, tumors were removed and minced into fine pieces in digestion buffer containing 0.1 mg/ml DNase I and 2.0 mg/ml collagenase type IV (Sigma, St Louis, MO). Samples were incubated in digestion buffer at 371C for 30 min, filtered through a 70-mm filter (Millipore Bedford, MA) and washed twice with RPMI 1640 plus 10% FBS. Cells were then collected and washed twice with PBS containing with 1% BSA and 0.1% sodium azide and stained with FITC-labeled monoclonal antibodies against CD3, CD4 and MAC-1 and PE-labeled monoclonal antibodies against CD8 and CD25 (all from Immunotech, Marseille, France). Cells stained with each monoclonal antibody were quantified by FACSCalibur as described above. The percentages of CD3-, CD4-, CD8-, CD25-and MAC-1-positive cells infiltrating into the tumors were compared between the control (PBS) and PDBA/pmMIGHIP-10 groups (PDBA/pmMIG/IP-10 complex).
Statistical analysis. All data are expressed as mean7s.e. Statistical significance of differences between groups was determined by non-parametric Mann-Whitney U-test. Differences in tumor growth were analyzed with the repeated measures analysis of variance (ANOVA) test. A log-rank test was used to compare survival rates between MIG/IP-10 gene therapy with PDBA M Tominaga et al the different groups. Po0.05 was considered statistically significant.
Results
Study 1
Efficiency of PDBA-mediated gene delivery to C1300 mouse neuroblastoma cells. To examine the efficiency of PDBA-mediated gene delivery, we transferred the EGFP plasmid to C1300 cells. Fluorescence microscopy revealed that expression of EGFP was significantly higher in cells with PDBA-mediated transfer than in those incubated with EGFP plasmid alone (Figure 1 ). FACS analysis revealed that 21.4% of C1300 cells with PDBA-mediated gene transfer were positive for EGFP, whereas only 0.04% of cells exposed EGFP plasmid alone were positive for EGFP (Figure 1 ). These findings indicate that a PDBA-mediated gene delivery system can effectively transfer plasmids into C1300 cells. were not detected in control supernatants. The mean levels of mMIG and mIP-10 were 10 times higher in the PDBA/pmMIGHIP-10 group than in the pmMIGHIP10 group at 24, 48 and 72 h after transfection. Levels of expression of the MIG and IP-10 proteins for 7 days after gene transfection are shown in Figure 3 . MIG and IP-10 levels were highest from days 1 to 3. Expression of MIG and IP-10 proteins decreased gradually; however, MIG and IP-10 protein levels were produced until at least day 7.
Effects of MIG and IP-10 on the chemotactic responses of CD3
þ , CD4 þ , CD8 þ and CD25 þ lymphocytes and MAC-1 þ cells. Lymphoid cells obtained from splenocytes showed significant migration in response to 100 ng/ml but not 10 ng/ml conditioned media purified MIG and IP-10 ( Table 1) . Supernatants of cells transfected with PDBA/pmMIGHIP-10 complexes also induced significant migration of cells, and the number of migrated cells was higher than that with pmMIGHIP-10 or control medium ( Table 1 ). The distributions of the subsets of these migrated lymphoid cells, including CD3-, CD4-, CD8-, CD25-and MAC-1-positive cells, are shown in Table 2 . The numbers of migrated CD4-and CD8-positive T cells were two times higher, and the numbers of CD25-and MAC-1-positive cells were five times higher in response to supernatants of PDBA/pmMIGHIP-10 complex-treated cells than to control cells. Mac-1 is a marker levels of mMIG and mIP-10 were measured by ELISA. mMIG and mIP-10 levels in tumor lysates at 24 and 72 h after a single injection of PDBA/pmMIGHIP-10 complex (days 8 and 10 after the tumor inoculation) are shown in Figure 6 . The mean levels of MIG and IP-10 were 12 times higher than those of PBS-injected controls.
Migration TILs induced by intratumoral MIG and IP-10 gene transfer. To examine the mechanism of this tumor suppression by PDBA-mediated transfer of the MIG and IP-10 genes, the subsets of lymphocytes that infiltrated into the tumor environment were examined by flow cytomety. The distributions of the subsets of CD3-, CD4-, CD8-, CD25-and MAC-1-positive cells are shown in Table 3 
Discussion
Chemokines are a superfamily of small (8-14 kDa), secreted basic proteins that regulate migration and invasion of leukocytes into tissues through interactions with their specific receptors, which are members of the Figure 5 Long-term survival of animals after treatment. On days 7 and 14 after tumor inoculation, mice received intratumoral injections of the PDBA/pmMIGHIP-10 complex, PDBA/pEGFP complex (gene transfer control), pmMIGHIP-10 alone (plasmid control) or PBS (control). PDBA/pEGFP complex, PDBA/pEGFP complex and PBS groups each comprised nine animals, and the pmMIGHIP-10 alone group comprised seven animals. *Po0.01vs other groups. IP-10, interferon g-inducible protein-10; PBS, phosphate-buffered saline; s.e., standard error of the mean.
MIG/IP-10 gene therapy with PDBA M Tominaga et al superfamily of seven-transmembrane domain G-proteincoupled receptors. 30, 31 Chemokines attract specific immune cells to inflammatory disease sites and normal lymphoid tissues. 31 Because of these properties, chemokines are considered possible candidates for cancer immunotherapies, which are based on the premise that tumor cells can be eradicated by immune cells that have migrated into and accumulated in the tumor tissue. 32 In addition, it is known that some tumor cells express levels of chemokines that are lower than those expressed by normal cells. 33 To date, more than 40 chemokines have been identified, and several chemokines have been proposed and tested either alone or with an adjuvant as candidates for cancer treatment. [34] [35] [36] The number of TILs is related significantly to outcomes in patients with a variety of malignancies. [18] [19] [20] [21] [22] [23] Recently, Hirano et al. 23 reported a close relation between TILs and MIG and IP-10 expression in hepatocellular carcinoma. 23 In the present study, we found that PDBA-mediated MIG and IP-10 gene therapy induces significant chemotaxis of lymphocytes in vitro. Lymphocytes showed significant migration in response to 100 ng/ml MIG and IP-10 ( Table 1) . PDBA-mediated MIG and IP-10 gene transfer led to expression of MIG and IP-10 proteins at levels greater than 20 ng/ml/10 6 cells (Figure 2 ), and this MIG and IP-10 level was sufficient to cause migration of lymphocytes similar to 100 ng/ml of MIG and IP-10 ( Table 2 ). In our in vivo study, MIG and IP-10 gene therapy inhibited the growth of solid tumors in a mouse model of neuroblastoma ( Figure 4 ) and extended survival of treated mice ( Figure 5 ). We also confirmed by ELISA that intratumoral levels of MIG and IP-10 after PDBAmediated gene transfer were more than 500 pg/mg protein ( Figure 6 ). T lymphocytes, especially cytotoxic T cells and activated T cells, were attracted into the tumor environment in response to the exogenous expression of MIG and IP-10 (Table 3) .
MIG and IP-10 are members of the CXC chemokine family, and expression of MIG and IP-10 are markedly induced by IFNg. Both MIG and IP-10 lack the ERL sequence motif associated with chemotaxis of neutrophils and angiogenesis. 6 MIG and IP-10 share the same receptor (CXCR3), and both have chemotactic effects on activated T lymphocytes. 6, 10, 37 In addition, MIG and IP-10 have been shown to inhibit angiogenesis. 38, 39 MIG and IP-10 have antitumor properties, which result from their actions on lymphocytes. 27, 40, 41 Recently, the antitumor effects of combined IL-12 and IP-10 gene transfer with an adenoviral vector, 42 the synergistic antitumor effect of lymphotactin and IP-10 gene transfer with adenoviral vector 43 and the synergistic effects of adoptive T-cell therapy and intratumoral IP-10 gene transfer method with adenoviral vector 41 were reported in animal models. A study of vector expressing IP-10 revealed both antitumor and antimetastatic effects of IP-10 in mice. 27 There are several methods for transfer of genes to tumor cells, including viral transfection, plasmid-based gene transfer and physical methods such as electroporation. Viral vectors provide highly efficient methods for gene delivery to a variety of tissues; however, viral vectors cannot be used repeatedly because of antigenicity. 44 In addition, delivery of a viral vector to a specific tissue is difficult. However, the most important problem is the safety of viral vectors. 44 Despite improved safety, viral vectors still have transient toxic effects in animals and humans. In contrast, the efficiencies of physical methods of gene transfer have been improved. Although in vivo electroporation dramatically increases transfection efficiency for a variety of tissues, substantial damage to the tissue subjected to the electrotransfer procedure can occur. 45 Non-viral methods might resolve such problems. Non-viral vectors may be good clinical options because they are safer and less labor intensive than virus-based methods; however, present non-viral transfection efficiencies need to be improved. Bettina et al. 46 reported a 2379% transfection efficiency for LipofectAMINEt (Invitrogen)-based transfection of primary malignant lymphoma cells with vector expressing the IL-2 gene. However, studies of other lipofection agents, including PrimeFectort (EquiBio, Ashford, UK), EasyFectort (EquiBio) and SuperFectt (Qiagen) have yielded transfection efficiencies lower than those of electroporation and LipofectAMINEt. 46 In the present study, the efficiency of PDBA-mediated gene transfer was 21.4%, which is similar to that of LipofectAMINEt. Therefore, PDBA-mediated gene transfer appears to be a safe and effective method. The efficiencies of PDBA-mediated gene transfer to other tumor cell lines, such as melanoma 15 and colon (18.6%), and pancreatic (20.3%) cancers (unpublished data) were relatively high. PDBA-mediated gene transfer may be one of the most useful options for treatment of cancer.
MIG and IP-10 protein levels were highest on days 3 to 5 after gene transfer. Expression decreased gradually; however, expression of the MIG and IP-10 proteins was observed for at least 7 days. PDBA-mediated gene transfer can be easily and safely repeated so that levels of the MIG and IP-10 proteins can be maintained in the tumor sites. PDBA-mediated gene transfer would differ from viral vector and electroporation with regard to repeated transfection.
We recently reported a phase-I study of a DC-based immunotherapy against hepatocellular carcinoma.
47 This DC-based immunotherapy appeared to be an attractive strategy for the treatment of malignant tumors because cytotoxic T lymphocytes were found to be strongly activated in vivo. 48 Such immunotherapeutic approaches may accelerate the infiltration of lymphocytes into tumors, thereby inhibiting tumor growth. In the present study, we demonstrated that T lymphocytes, especially cytotoxic T lymphocytes (CD8-positive T cells), were attracted into the tumor environment by PDBA-mediated MIG and IP-10 gene transfer in vivo. DC therapy combined with PDBA-mediated chemokine gene delivery may accelerate infiltration of lymphocytes into tumors and act cooperatively to enhance the antitumor effect.
In summary, transfer of the MIG and IP-10 genes into solid tumors with a PDBA-mediated gene delivery system significantly inhibited tumor growth in vivo and prolonged survival time of mice with solid tumors. Therefore, MIG and IP-10 gene therapy may be a useful strategy for treatment of solid tumors.
